HOLX News and Press, Hologic Inc. From 07/31/22

Active Motif Incorporated Licenses Targeted Transposition to Diagenode S.A. Technology Canada NewsWire CARLSBAD, Calif. , July 31, 2022 /CNW/ -- Active Motif Incorporated, a company with the vision of bringing epigenetics more deeply into precis...

Hologic, Inc. (HOLX) Q3 2022 Results Earnings Conference Call July 28, 2022, 04:30 PM ET Company Participants Ryan Simon - Vice President, Investor Relations Stephen MacMillan - Chairman, President and Chief Executive Officer Karleen Oberton - Chief Financial Off...

Image source: The Motley Fool. Hologic (NASDAQ: HOLX) Q3 2022 Earnings Call Jul 27, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Hologic (HOLX) Q3 2022 Earnings Call Transcript

We believe the healthcare sector's strong growth momentum with average revenue growth of 3.8% QoQ indicates a positive outlook, with the equipment industry forecasted at a market CAGR of 5.5%. For the healthcare equipment industry, we believe the outlook is supported by the average gu...

Hologic press release ( NASDAQ: HOLX ): Q3 Non-GAAP EPS of $0.95 beats by $0.25 . Revenue of $1B (-14.5% Y/Y) beats by $103.29M . Global Organic Molecular Diagnostics ex-COVID-19 Revenue Grows Over 20% in Constant Currency. Company Again Increases Full-Year...

– Revenue of $1.003 Billion, GAAP Diluted EPS of $0.90, and Non-GAAP Diluted EPS of $0.95 All Significantly Ahead of Expectations – – Global Organic Molecular Diagnostics ex-COVID-19 Revenue Grows Over 20% in Constant Currency – – Company Again...

Hologic ( NASDAQ: HOLX ) is scheduled to announce FQ3 earnings results on Wednesday, July 27th, after market close. The consensus EPS estimate is $0.70 and consensus revenue estimate is $896.71M. Over the last 2 years, HOLX has beaten EPS estimates 88% of the time ...

Although the healthcare sector has largely resisted this year's downward pressure, it is likely to succumb as pressure increases. Healthcare stocks have a well-deserved reputation for cyclical defense, but they are more likely to underperform in "secular" bear markets. Healthcare ...

BofA Securities has downgraded diagnostics products and medical imaging systems company Hologic ( NASDAQ: HOLX ) citing headwinds from supply chain issues, foreign exchange, and COVID-19. The firm also cut its price target to $75 from $81 (~6% upside based on Tue...

BTIG has downgraded Hologic, Inc. ( NASDAQ: HOLX ), a developer of medical equipment targeting female health, to Neutral from Buy, noting mainly the macro-related issues which, according to the analysts, generally fell outside the company’s control. Noting its previ...